The stock of Kalaris Therapeutics Inc (NASDAQ: KLRS) has decreased by -10.51 when compared to last closing price of 3.33.Despite this, the company has seen a loss of -11.83% in its stock price over the last five trading days. globenewswire.com reported 2025-05-14 that Actively enrolling nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina; initial clinical data is expected in Q4 2025
Is It Worth Investing in Kalaris Therapeutics Inc (NASDAQ: KLRS) Right Now?
Moreover, the 36-month beta value for KLRS is 0.49. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for KLRS is 4.53M and currently, short sellers hold a 1.17% of that float. On May 22, 2025, KLRS’s average trading volume was 38.76K shares.
KLRS’s Market Performance
The stock of Kalaris Therapeutics Inc (KLRS) has seen a -11.83% decrease in the past week, with a -55.92% drop in the past month, and a -69.68% fall in the past quarter. The volatility ratio for the week is 16.17%, and the volatility levels for the past 30 days are at 15.25% for KLRS. The simple moving average for the past 20 days is -36.05% for KLRS’s stock, with a -75.77% simple moving average for the past 200 days.
Analysts’ Opinion of KLRS
Many brokerage firms have already submitted their reports for KLRS stocks, with Leerink Partners repeating the rating for KLRS by listing it as a “Outperform.” The predicted price for KLRS in the upcoming period, according to Leerink Partners is $20 based on the research report published on May 07, 2025 of the current year 2025.
KLRS Trading at -56.56% from the 50-Day Moving Average
After a stumble in the market that brought KLRS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.66% of loss for the given period.
Volatility was left at 15.25%, however, over the last 30 days, the volatility rate increased by 16.17%, as shares sank -57.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -68.60% lower at present.
During the last 5 trading sessions, KLRS fell by -11.83%, which changed the moving average for the period of 200-days by -83.17% in comparison to the 20-day moving average, which settled at $4.66. In addition, Kalaris Therapeutics Inc saw -69.15% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KLRS starting from Hagen Brett R, who sale 907 shares at the price of $8.97 back on Mar 26 ’25. After this action, Hagen Brett R now owns 1,925 shares of Kalaris Therapeutics Inc, valued at $8,135 using the latest closing price.
Stock Fundamentals for KLRS
The total capital return value is set at 22.11. Equity return is now at value -41.96, with -31.28 for asset returns.
Currently, EBITDA for the company is -14.01 million with net debt to EBITDA at 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.31.
Conclusion
To wrap up, the performance of Kalaris Therapeutics Inc (KLRS) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
